# AMX0035 in Adult Patients With Wolfram Syndrome

> **NCT05676034** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Amylyx Pharmaceuticals Inc.** · enrollment: 12 (actual)

## Conditions studied

- Wolfram Syndrome

## Interventions

- **DRUG:** AMX0035

## Key facts

- **NCT ID:** NCT05676034
- **Lead sponsor:** Amylyx Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-03
- **Primary completion:** 2024-07-23
- **Final completion:** 2028-05-31
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05676034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05676034, "AMX0035 in Adult Patients With Wolfram Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05676034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*